Co-Authors
This is a "connection" page, showing publications co-authored by PADMANEE SHARMA and ANDREW FUTREAL.
Connection Strength
0.876
-
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
Score: 0.202
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.188
-
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
Score: 0.181
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.142
-
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq. 2023 Jul 18.
Score: 0.057
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.048
-
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77.
Score: 0.032
-
State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012 Jul; 10(7):859-80.
Score: 0.026